Tables S1-6 from miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense

Supplementary Tables 1-6 Supp. Table 1: Clinicopathological characteristics of breast cancer patients whose tumours were profiled by miRNA expression microarrays to identify miRNAs associated with local relapse following radiotherapy. Supp. Table 2: Clinicopathological characteristics of RT-treated breast cancer patients from "Rotterdam", "Uppsala", and "Mainz" cohorts that were analysed for biomarker validation Supp. Table 3: Clinicopathological characteristics of RT- and non-RT treated breast cancer patients from "Lund" cohort that were analysed for biomarker validation Supp. Table 4: Clinicopathological characteristics of RT-treated breast cancer patients from "Oxford" and "METABRIC" cohorts that were analysed to validate miR-139-5p as a biomarker Supp. Table 5: Primer sequences for miR-139-5p targets (Roche Universal Probe Library QPCR system) Supp. Table 6: IC50s for 15 DNA damaging compounds in 10 breast cancer cell lines. Also listed are DNA mutations significantly correlated (p<0.05) with sensitivity to each drug, and the basal miR-139-5p expression levels for each cell line (measured by QPCR as a % of mean housekeeping gene expression). IC50 and mutation data extracted from the Genomics of Drug Sensitivity in Cancer (GDSC) database [Nucl. Acids Res. 2013 Database issue. PMID:23180760].